Discussion stirs around Bio-Techne Corporation (NASDAQ:TECH) this week; here is what analysts are saying.

April 22, 2018 - By reb123z

Bio-Techne Corporation (NASDAQ:TECH) LogoInvestors sentiment decreased to 0.98 in Q4 2017. Its down 0.23, from 1.21 in 2017Q3. It dropped, as 27 investors sold Bio-Techne Corporation shares while 88 reduced holdings. 34 funds opened positions while 79 raised stakes. 35.53 million shares or 1.06% less from 35.91 million shares in 2017Q3 were reported.
Renaissance Technologies Limited Liability Com has 0.05% invested in Bio-Techne Corporation (NASDAQ:TECH). Rice Hall James Associates Llc, California-based fund reported 19,271 shares. Magnetar Fincl Ltd holds 2,306 shares or 0.01% of its portfolio. Atlanta Capital Mgmt L L C has invested 1.32% in Bio-Techne Corporation (NASDAQ:TECH). 25 were reported by Brown Brothers Harriman Com. Principal Fincl holds 198,533 shares or 0.02% of its portfolio. First Mercantile Trust invested 0.11% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Ent Fincl Service holds 0% or 29 shares. California Employees Retirement System holds 75,930 shares. New Mexico Educational Retirement Board has 9,273 shares. Tiaa Cref Mgmt Lc reported 117,395 shares. Kornitzer Mgmt Ks has 0.29% invested in Bio-Techne Corporation (NASDAQ:TECH). Moreover, Sit Investment Associates Incorporated has 0.02% invested in Bio-Techne Corporation (NASDAQ:TECH). State Of Alaska Department Of Revenue holds 0.03% or 9,399 shares in its portfolio. Shelton Cap Mngmt has 2,821 shares for 0.02% of their portfolio.

Since February 13, 2018, it had 0 buys, and 1 insider sale for $680,303 activity.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 6 analysts covering Bio-Techne Corporation (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Bio-Techne Corporation had 9 analyst reports since October 24, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 23 by Robert W. Baird. The stock of Bio-Techne Corporation (NASDAQ:TECH) has “Buy” rating given on Tuesday, February 6 by Robert W. Baird. Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) rating on Tuesday, October 31. Robert W. Baird has “Buy” rating and $140.0 target. The firm has “Hold” rating given on Wednesday, February 7 by Stephens. Deutsche Bank maintained Bio-Techne Corporation (NASDAQ:TECH) on Thursday, March 1 with “Buy” rating. On Wednesday, February 7 the stock rating was maintained by Craig Hallum with “Buy”. Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) on Thursday, January 18 with “Buy” rating. The company was maintained on Tuesday, December 5 by Leerink Swann. Below is a list of Bio-Techne Corporation (NASDAQ:TECH) latest ratings and price target changes.

01/03/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $163 Maintain
07/02/2018 Broker: Stephens Rating: Hold New Target: $142.0 Maintain
07/02/2018 Broker: Craig Hallum Rating: Buy New Target: $160.0 Maintain
06/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $157.0 Maintain
18/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $154.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy Maintain
31/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $140.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $126.0 Maintain
24/10/2017 Broker: Citigroup Rating: Buy New Target: $145.0

The stock increased 0.39% or $0.59 during the last trading session, reaching $152.78. About 158,288 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 45.31% since April 22, 2017 and is uptrending. It has outperformed by 33.76% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.73 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 50.24 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.